These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 15938031)
1. Dual blockade of the renin-angiotensin system: the ultimate treatment for renal protection? Codreanu I; Perico N; Remuzzi G J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S34-8. PubMed ID: 15938031 [TBL] [Abstract][Full Text] [Related]
2. Prevention of progression and remission/regression strategies for chronic renal diseases: can we do better now than five years ago? Perico N; Codreanu I; Schieppati A; Remuzzi G Kidney Int Suppl; 2005 Sep; (98):S21-4. PubMed ID: 16108966 [TBL] [Abstract][Full Text] [Related]
3. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance? Vogt L; Kocks MJ; Laverman GD; Navis G Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515 [TBL] [Abstract][Full Text] [Related]
4. Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease. Andersen NH; Mogensen CE Curr Hypertens Rep; 2004 Oct; 6(5):369-76. PubMed ID: 15341690 [TBL] [Abstract][Full Text] [Related]
5. Can dual blockade of the renin-angiotensin system reduce progression of kidney disease beyond monotherapy? Brewster UC; Perazella MA Expert Opin Drug Saf; 2004 Jan; 3(1):9-23. PubMed ID: 14680458 [TBL] [Abstract][Full Text] [Related]
6. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154 [TBL] [Abstract][Full Text] [Related]
7. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II). Jacobsen PK J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):55-68. PubMed ID: 16470484 [TBL] [Abstract][Full Text] [Related]
8. Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects? Kujal P; Chábová VČ; Vernerová Z; Walkowska A; Kompanowska-Jezierska E; Sadowski J; Vaňourková Z; Husková Z; Opočenský M; Skaroupková P; Schejbalová S; Kramer HJ; Rakušan D; Malý J; Netuka I; Vaněčková I; Kopkan L; Cervenka L Clin Exp Pharmacol Physiol; 2010 Dec; 37(12):1159-69. PubMed ID: 20880190 [TBL] [Abstract][Full Text] [Related]
9. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency. Pisoni R; Faraone R; Ruggenent P; Remuzzi G J Nephrol; 2002; 15(4):428-30. PubMed ID: 12243375 [TBL] [Abstract][Full Text] [Related]
10. Treatment of type 2 diabetic nephropathy by blockade of the renin-angiotensin system: a comparison of angiotensin-converting-enzyme inhibitors and angiotensin receptor antagonists. Hsueh WA Curr Opin Pharmacol; 2002 Apr; 2(2):182-8. PubMed ID: 11950631 [TBL] [Abstract][Full Text] [Related]
11. Intensified inhibition of renin-angiotensin system: a way to improve renal protection? Cravedi P; Ruggenenti P; Remuzzi G Curr Hypertens Rep; 2007 Nov; 9(5):430-6. PubMed ID: 18177592 [TBL] [Abstract][Full Text] [Related]
12. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy. Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237 [TBL] [Abstract][Full Text] [Related]
13. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185 [TBL] [Abstract][Full Text] [Related]
14. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease. Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466 [TBL] [Abstract][Full Text] [Related]
15. [Risk and prevention of diabetic nephropathy]. Ravera M; Re M; Deferrari G G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442 [TBL] [Abstract][Full Text] [Related]
16. Renal protection in diabetes: is it affected by glucose control or inhibition of the renin-angiotensin pathway? Mandal AK; Hiebert LM Clin Nephrol; 2008 Mar; 69(3):169-78. PubMed ID: 18397715 [TBL] [Abstract][Full Text] [Related]
17. The Remission Clinic approach to halt the progression of kidney disease. ; J Nephrol; 2011; 24(3):274-81. PubMed ID: 21534237 [TBL] [Abstract][Full Text] [Related]
18. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855 [TBL] [Abstract][Full Text] [Related]
19. Dual renin-angiotensin system blockade for nephroprotection. Ruggenenti P Nephrol Ther; 2017 Apr; 13 Suppl 1():S43-S45. PubMed ID: 28577742 [TBL] [Abstract][Full Text] [Related]
20. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease. St Peter WL; Odum LE; Whaley-Connell AT Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]